A dialog on the first 20 years of PML research and the next 20 ahead

Frontiers in Oncology

Volumn 4 FEB, Issue , 2014, Pages

  Bernardi, Rosa ^a   Pandolfi, Pier Paolo ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Leukemia; Nuclear bodies; PML; Tumor suppressor

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL NUCLEUS INCLUSION BODY; CLINICAL RESEARCH; DNA DAMAGE; GENE; HEMATOPOIETIC STEM CELL; LEUKEMIA; METABOLISM; NONHUMAN; PROMYELOCYTIC LEUKEMIA; PROMYELOCYTIC LEUKEMIA GENE; TUMOR SUPPRESSOR GENE;

EID: 84898032907     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00023     Document Type: Article

References (46)

1. PandolfiPP, Grignani F, Alcalay M, Mencarelli A, Biondi A, LoCoco F, et al. Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. Oncogene (1991) 6(7):1285-92.
2. de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell (1991) 66(4):675-84. doi: 10.1016/0092-8674(91)90113-D
3. Kakizuka A, Miller WH Jr, Umesono K, Warrell RP Jr, Frankel SR, Murty VV, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell (1991) 66(4):663-74. doi:10.1016/0092-8674(91)90112-C
4. Goddard AD, Borrow J, Freemont PS, Solomon E. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science (1991) 254(5036):1371-4. doi:10.1126/science.1720570
5. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C, et al. Role of PML in cell growth and the retinoic acid pathway. Science (1998) 279(5356):1547-51. doi:10.1126/science.279.5356.1547
6. de The H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature (1990) 347(6293):558-61. doi:10.1038/347558a0
7. Longo L, Donti E, Mencarelli A, Avanzi G, Pegoraro L, Alimena G, et al. Mapping of chromosome 17 breakpoints in acute myeloid leukemias. Oncogene (1990) 5(10):1557-63.
8. Borrow J, Goddard AD, Sheer D, Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science (1990) 249(4976):1577-80. doi:10.1126/science.2218500
9. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, et al. The tripartite motif family identifies cell compartments. EMBO J (2001) 20(9):2140-51. doi:10.1093/emboj/20.9.2140
10. Jensen K, Shiels C, Freemont PS. PML protein isoforms and the RBCC/TRIM motif. Oncogene (2001) 20(49):7223-33. doi:10.1038/sj.onc.1204765
11. Bernardi R, PandolfiPP. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol (2007) 8(12):1006-16. doi:10.1038/nrm2277
12. Lallemand-Breitenbach V, de The H. PML nuclear bodies. Cold Spring Harb Perspect Biol (2010) 2(5):a000661. doi:10.1101/cshperspect.a000661
13. Daniel MT, Koken M, Romagne O, Barbey S, Bazarbachi A, Stadler M, et al. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood (1993) 82(6):1858-67.
14. Boisvert FM, Hendzel MJ, Bazett-Jones DP. Promyelocytic leukemia (PML) nuclear bodies are protein structures that do not accumulate RNA. J Cell Biol (2000) 148(2):283-92. doi:10.1083/jcb.148.2.283
15. Dellaire G, Bazett-Jones DP. PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. Bioessays (2004) 26(9):963-77. doi:10.1002/bies.20089
16. Dellaire G, Eskiw CH, Dehghani H, Ching RW, Bazett-Jones DP. Mitotic accumulations of PML protein contribute to the re-establishment of PML nuclear bodies in G1. J Cell Sci (2006) 119(Pt 6):1034-42. doi:10.1242/jcs.02817
17. Condemine W, Takahashi Y, Zhu J, Puvion-Dutilleul F, Guegan S, Janin A, et al. Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res (2006) 66(12):6192-8. doi:10.1158/0008-5472.CAN-05-3792
18. Brand P, Lenser T, Hemmerich P. Assembly dynamics of PML nuclear bodies in living cells. PMC Biophys (2010) 3(1):3. doi:10.1186/1757-5036-3-3
19. Nisole S, Maroui MA, Mascle XH, Aubry M, Chelbi-Alix MK. Differential roles of PML isoforms. Front Oncol (2013) 3:125. doi:10.3389/fonc.2013.00125
20. Lin HK, Bergmann S, PandolfiPP. Cytoplasmic PML function in TGF-beta signalling. Nature (2004) 431(7005):205-11. doi:10.1038/nature02783
21. Giorgi C, Ito K, Lin HK, Santangelo C, Wieckowski MR, Lebiedzinska M, et al. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science (2010) 330(6008):1247-51. doi:10.1126/science.1189157
22. Shimada N, Shinagawa T, Ishii S. Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein. Genes Cells (2008) 13(3):245-54. doi:10.1111/j.1365-2443.2008.01165.x
23. Jin G, Wang YJ, Lin HK. Emerging cellular functions of cytoplasmic PML. Front Oncol (2013) 3:147. doi:10.3389/fonc.2013.00147
24. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, PandolfiPP. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol (2004) 6(7):665-72. doi:10.1038/ncb1147
25. Mattsson K, Pokrovskaja K, Kiss C, Klein G, Szekely L. Proteins associated with the promyelocytic leukemia gene product (PML)-containing nuclear body move to the nucleolus upon inhibition of proteasome-dependent protein degradation. Proc Natl Acad Sci U S A (2001) 98(3):1012-7. doi:10.1073/pnas.031566998
26. Condemine W, Takahashi Y, Le Bras M, de The H. A nucleolar targeting signal in PML-I addresses PML to nucleolar caps in stressed or senescent cells. J Cell Sci (2007) 120(Pt 18):3219-27. doi:10.1242/jcs.007492
27. Mansour SL, Thomas KR, Capecchi MR. Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature (1988) 336(6197):348-52. doi:10.1038/336348a0
28. Ferbeyre G, de Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev (2000) 14(16):2015-27. doi:10.1101/gad.14.16.2015
29. Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W, et al. The function of PML in p53-dependent apoptosis. Nat Cell Biol (2000) 2(10):730-6. doi:10.1038/35036365
30. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature (2000) 406(6792):207-10. doi:10.1038/35018127
31. Bernassola F, Oberst A, Melino G, PandolfiPP. The promyelocytic leukaemia protein tumour suppressor functions as a transcriptional regulator of p63. Oncogene (2005) 24(46):6982-6. doi:10.1038/sj.onc.1208843
32. Dobbelstein M, Strano S, Roth J, Blandino G. p73-induced apoptosis: a question of compartments and cooperation. Biochem Biophys Res Commun (2005) 331(3):688-93. doi:10.1016/j.bbrc.2005.03.155
33. Bernardi R, Papa A, PandolfiPP. Regulation of apoptosis by PML and the PML-NBs. Oncogene (2008) 27(48):6299-312. doi:10.1038/onc.2008.305
34. Papa A, Cordon-Cardo C, Bernardi R, PandolfiPP. Compound in vivo inactivation of Pml and p53 uncovers a functional interaction in angiosarcoma suppression. Genes Cancer (2012) 3(9-10):599-603. doi:10.1177/1947601912473604
35. Haupt S, Mitchell C, Corneille V, Shortt J, Fox S, PandolfiPP, et al. Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. Cell Cycle (2013) 12(11):1722-31. doi:10.4161/cc.24805
36. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature (2008) 453(7198):1072-8. doi:10.1038/nature07016
37. Regad T, Bellodi C, Nicotera P, Salomoni P. The tumor suppressor Pml regulates cell fate in the developing neocortex. Nat Neurosci (2009) 12(2):132-40. doi:10.1038/nn.2251
38. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, et al. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature (2006) 442(7104):779-85. doi:10.1038/nature05029
39. Carracedo A, Weiss D, Leliaert AK, Bhasin M, de Boer VC, Laurent G, et al. A metabolic prosurvival role for PML in breast cancer. J Clin Invest (2012) 122(9):3088-100. doi:10.1172/JCI62129
40. Chuang YS, Huang WH, Park SW, Persaud SD, Hung CH, Ho PC, et al. Promyelocytic leukemia protein in retinoic acid-induced chromatin remodeling of Oct4 gene promoter. Stem Cells (2011) 29(4):660-9. doi:10.1002/stem.623
41. Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J, et al. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature (2008) 455(7214):813-7. doi:10.1038/nature07290
42. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, PandolfiPP. Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 441(7092):523-7. doi:10.1038/nature04809
43. Mazza M, Pelicci PG. Is PML a tumor suppressor? Front Oncol (2013) 3:174. doi:10.3389/fonc.2013.00174
44. Martin-Martin N, Sutherland JD, Carracedo A. PML: not all about tumor suppression. Front Oncol (2013) 3:200. doi:10.3389/fonc.2013.00200
45. Cheng X, Guo S, Liu Y, Chu H, Hakimi P, Berger NA, et al. Ablation of promyelocytic leukemia protein (PML) re-patterns energy balance and protects mice from obesity induced by a western diet. J Biol Chem (2013) 288(41):29746-59. doi:10.1074/jbc. M113.487595
46. Dos Santos GA, Kats L, PandolfiPP. Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. J Exp Med (2013) 210(13):2793-802. doi:10.1084/jem.20131121